drugset
drugset / Trial / NCT01089660

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

NCT01089660 ↗

Phase 2 Completed 202 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is designed to describe the immunogenicity of a pandemic A/H1N1 influenza vaccine in healthy adults given a lower vaccine dose and in a similar group given a full dose of the vaccine. The primary objective is to describe describe the immune response of the inactivated, split-virion swine-origin A/H1N1 influenza vaccine without adjuvant.

Timeline

Start
2010-03
Primary completion
2010-09
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Swine A/H1N1 influenza vaccine (split virion, inactivated) Vaccine 0.3 ml Intramuscular
Subject Swine A/H1N1 influenza vaccine (split virion, inactivated) Vaccine 0.5 ml Intramuscular

Indications

swine influenza